ASP Isotopes (NASDAQ:ASPI) Trading 7.8% Higher – Time to Buy?

ASP Isotopes Inc. (NASDAQ:ASPI) shares shot up 7.8% during trading on Friday . The company traded as high as $5.53 and last traded at $5.51. 2,210,445 shares were traded during trading, a decline of 57% from the average session volume of 5,136,980 shares. The stock had previously closed at $5.11.

ASP Isotopes News Roundup

Here are the key news stories impacting ASP Isotopes this week:

• Positive Sentiment: QLE (ASPI subsidiary) signed a non‑binding MOU with a large U.S. energy company to evaluate support for establishing advanced nuclear fuel‑cycle facilities in the U.S., a strategic step that could attract partner funding or offtake support for ASPI’s domestic fuel‑supply plans. GlobeNewswire Release
• Positive Sentiment: Market coverage highlights the MOU as strengthening ASPI’s role in the U.S. nuclear fuel supply chain, bringing investor attention to potential long‑term contract opportunities and government/utility interest. Benzinga Article MSN Coverage
• Positive Sentiment: Unusually large call‑option activity: investors bought ~24,907 call options (an ~82% increase vs. average daily call volume), which signals short‑term bullish positioning from derivatives traders and can amplify upward stock moves.
• Positive Sentiment: QLE appointed Nate Salpeter, Ph.D., as CTO — an experienced technical hire that supports execution credibility for engineering and process development tied to ASPI’s fuel‑cycle ambitions. Business Insider: CTO Appointment
• Positive Sentiment: Investor visibility increased after ASPI interviews are scheduled to air on the RedChip “Small Stocks, Big Money” show on Bloomberg TV, which can boost retail attention and trading volume. Dispatch Press Release
• Neutral Sentiment: Short‑interest reports in recent feeds show zero shares or NaN changes (data appears inconsistent), so there’s no clear short‑position signal to explain the move; treat short‑interest figures as unreliable until exchanges provide corrected data.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald assumed coverage on ASP Isotopes in a research report on Thursday, December 4th. They issued an “overweight” rating and a $13.00 price objective on the stock. Canaccord Genuity Group restated a “buy” rating and set a $11.00 target price on shares of ASP Isotopes in a research report on Monday, November 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $13.00.

ASP Isotopes Trading Up 8.6%

The stock’s 50 day simple moving average is $6.22 and its 200 day simple moving average is $7.68. The firm has a market cap of $615.16 million, a PE ratio of -4.27 and a beta of 3.55. The company has a debt-to-equity ratio of 1.04, a quick ratio of 6.10 and a current ratio of 6.14.

Insider Buying and Selling at ASP Isotopes

In related news, CFO Heather Kiessling sold 80,000 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $5.80, for a total value of $464,000.00. Following the transaction, the chief financial officer owned 732,500 shares of the company’s stock, valued at $4,248,500. This represents a 9.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert Ainscow sold 8,438 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $6.20, for a total value of $52,315.60. Following the sale, the chief executive officer owned 1,546,255 shares in the company, valued at $9,586,781. The trade was a 0.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 14.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ASP Isotopes

Several institutional investors have recently modified their holdings of ASPI. Quantbot Technologies LP purchased a new position in shares of ASP Isotopes during the 3rd quarter valued at about $34,000. Ameritas Investment Partners Inc. boosted its stake in ASP Isotopes by 41.2% in the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock worth $40,000 after buying an additional 1,600 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after buying an additional 2,548 shares in the last quarter. IFP Advisors Inc bought a new position in ASP Isotopes during the fourth quarter valued at approximately $48,000. Finally, Pictet Asset Management Holding SA bought a new position in ASP Isotopes during the fourth quarter valued at approximately $61,000. 16.80% of the stock is currently owned by institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.